Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV(2)) in relapsed and refractory lymphomas Journal Article

  

Authors:	Crown, J. P.; Gulati, S.; Straus, D. J.; Kolitz, J.; Heelan, R.; O'Brien, J.; Lee, B. J.; Portlock, C.; Bertino, J.
Article Title:	Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV(2)) in relapsed and refractory lymphomas
Abstract:	As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease. An over-all partial response rate of 41% was observed. Although useful responses were seen, the absence of complete remissions is disappointing. © 1991 Kluwer Academic Publishers.
Keywords:	adolescent; adult; clinical article; cancer combination chemotherapy; prospective studies; phase 2 clinical trial; bone marrow suppression; etoposide; antineoplastic combined chemotherapy protocols; relapse; recurrence; vinblastine; hodgkin disease; mitoxantrone; lymphoma; remission induction; phase 1 clinical trial; intravenous drug administration; mitoguazone; oral drug administration; middle age; drug evaluation; prognosis; human; priority journal; article; support, non-u.s. gov't; relapsed/refractory lymphomas
Journal Title:	Investigational New Drugs
Volume:	9
Issue:	2
ISSN:	0167-6997
Publisher:	Springer
Date Published:	1991-05-01
Start Page:	185
End Page:	186
Language:	English
DOI:	10.1007/bf00175086
PUBMED:	1874601
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025818380&doi=10.1007%2fBF00175086&partnerID=40&md5=4da35b24df5f8914d2245b8a2c4a9de4
Notes:	Article -- Export Date: 27 September 2019 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/154439